Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Baldwin Investment Management LLC

Baldwin Investment Management LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,891 shares of the pharmaceutical company’s stock after purchasing an additional 135 shares during the period. Vertex Pharmaceuticals accounts for 0.7% of Baldwin Investment Management LLC’s portfolio, making the stock its 18th biggest position. Baldwin Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $5,530,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of VRTX. Transamerica Financial Advisors Inc. grew its position in Vertex Pharmaceuticals by 1,673.1% in the 3rd quarter. Transamerica Financial Advisors Inc. now owns 8,174 shares of the pharmaceutical company’s stock worth $3,802,000 after purchasing an additional 7,713 shares during the last quarter. Principal Street Partners LLC boosted its position in Vertex Pharmaceuticals by 26.4% during the 3rd quarter. Principal Street Partners LLC now owns 3,010 shares of the pharmaceutical company’s stock worth $1,406,000 after acquiring an additional 629 shares during the period. Avestar Capital LLC grew its stake in shares of Vertex Pharmaceuticals by 3.4% in the third quarter. Avestar Capital LLC now owns 3,156 shares of the pharmaceutical company’s stock worth $1,468,000 after purchasing an additional 104 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Vertex Pharmaceuticals by 4.9% during the third quarter. Brooklyn Investment Group now owns 1,873 shares of the pharmaceutical company’s stock valued at $871,000 after purchasing an additional 87 shares during the period. Finally, D.A. Davidson & CO. increased its holdings in shares of Vertex Pharmaceuticals by 12.6% during the third quarter. D.A. Davidson & CO. now owns 5,475 shares of the pharmaceutical company’s stock valued at $2,546,000 after purchasing an additional 611 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares of the company’s stock, valued at $4,987,006. This represents a 27.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The trade was a 12.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,445 shares of company stock valued at $2,218,394. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Piper Sandler increased their target price on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. UBS Group boosted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Oppenheimer cut their price objective on Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $504.38.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $467.07 on Wednesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $120.28 billion, a price-to-earnings ratio of -234.71 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12 month low of $346.29 and a 12 month high of $519.88. The firm has a 50 day moving average of $473.27 and a two-hundred day moving average of $474.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.